| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/01/2002 | CA2431144A1 Cell adhesion proteins |
| 08/01/2002 | CA2429034A1 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 08/01/2002 | CA2427647A1 Nucleic acid modification enzymes |
| 08/01/2002 | CA2426102A1 Method of diagnosing and treating cartilaginous disorders |
| 08/01/2002 | CA2424402A1 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections |
| 07/31/2002 | EP1227152A1 Bacterial strain and genome of bifidobacterium |
| 07/31/2002 | EP1227105A1 Ghsr ligand polypeptides and dnas thereof |
| 07/31/2002 | EP1227098A1 Triazolopurine derivatives, drug compositions containing the same and adenosine a3 receptor affinitive agents |
| 07/31/2002 | EP1227092A2 Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties |
| 07/31/2002 | EP1227091A2 Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties |
| 07/31/2002 | EP1227090A1 Amine derivatives |
| 07/31/2002 | EP1227085A1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 07/31/2002 | EP1227083A1 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS |
| 07/31/2002 | EP1226830A2 Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia |
| 07/31/2002 | EP1226826A1 Remedies |
| 07/31/2002 | EP1226823A2 Method of treating certain cancers using an estrogen agonist/antagonist |
| 07/31/2002 | EP1226822A2 Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same |
| 07/31/2002 | EP1226441A1 Protein tyrosine kinase receptor polynucleotides, polypeptides, and antibodies |
| 07/31/2002 | EP1226438A1 Composite nanospheres and their conjugates with biomolecules |
| 07/31/2002 | EP1226279A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 07/31/2002 | EP1226252A2 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226251A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226250A2 Gpcr-kd5 polypeptides and dna sequences thereof |
| 07/31/2002 | EP1226249A2 Follistatin-related protein zfsta4 |
| 07/31/2002 | EP1226245A2 Hybrid adaptor receptors |
| 07/31/2002 | EP1226243A2 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 07/31/2002 | EP1226242A1 Human cub-domain-containing protein and gene encoding the same |
| 07/31/2002 | EP1226237A2 Method of identifying inhibitors of cdc25 |
| 07/31/2002 | EP1226168A1 Ligand activated transcriptional regulator proteins |
| 07/31/2002 | EP1226160A2 Novel antiarrhythmic peptides |
| 07/31/2002 | EP1226159A1 Substituted dipeptides having nos inhibiting activity |
| 07/31/2002 | EP1226154A1 Estradiol conjugates and uses thereof |
| 07/31/2002 | EP1226151A2 Gene expression directed by a super-psa promoter |
| 07/31/2002 | EP1226150A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 07/31/2002 | EP1226146A2 Quinoline and naphthyridine carboxylic acid antibacterials |
| 07/31/2002 | EP1226144A1 Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| 07/31/2002 | EP1226143A2 Imidazopyridine derivatives used as phosphodiesterase vii inhibitors |
| 07/31/2002 | EP1226141A1 Heterocyclic substituted pyrazolones |
| 07/31/2002 | EP1226138A1 Fab i inhibitors |
| 07/31/2002 | EP1226137A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 07/31/2002 | EP1226136A2 Tyrosine kinase inhibitors |
| 07/31/2002 | EP1226131A2 Isoxazolecarboxamide derivatives |
| 07/31/2002 | EP1226128A1 New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds |
| 07/31/2002 | EP1226126A1 Pyrimidine derivatives |
| 07/31/2002 | EP1226119A2 Tyrosine kinase inhibitors |
| 07/31/2002 | EP1226115A1 Novel carbamates and ureas |
| 07/31/2002 | EP1226112A2 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 07/31/2002 | EP1226110A1 Bicyclic amino acids as pharmaceutical agents |
| 07/31/2002 | EP1226109A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 07/31/2002 | EP1226104A1 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 07/31/2002 | EP1225956A1 Method and compositions for administering taxanes orally to human patients |
| 07/31/2002 | EP1225919A1 Treatment of cancer |
| 07/31/2002 | EP1225913A1 Use of nitric oxide for the treatment of airway constriction |
| 07/31/2002 | EP1225911A1 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1) |
| 07/31/2002 | EP1225910A2 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 07/31/2002 | EP1225907A1 Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions |
| 07/31/2002 | EP1225901A2 Uses and compositions for treating platelet-related disorders using anagrelide |
| 07/31/2002 | EP1225900A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 07/31/2002 | EP1225896A1 Isoxazole derivatives to be used as phosphodiesterase vii inhibitors |
| 07/31/2002 | EP1225895A1 Fab i inhibitors |
| 07/31/2002 | EP1225894A1 Fab i inhibitors |
| 07/31/2002 | EP1225884A1 Method for administering a phosphodiesterase 4 inhibitor |
| 07/31/2002 | EP1225882A1 Selective cox-2 inhibitory novel esters from indolealkanols and novel amides from indolealkylamines |
| 07/31/2002 | EP1225881A1 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
| 07/31/2002 | EP1225880A2 Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
| 07/31/2002 | EP1225878A1 Treatment of emphysema using rar selective retinold agonists |
| 07/31/2002 | EP1225877A2 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 07/31/2002 | EP1225866A2 Method and compositions for treating pulmonary diseases |
| 07/31/2002 | EP1225810A1 Method for treatment of chronic venous insufficiencies using an extract of red vine leaves |
| 07/31/2002 | EP1102783A4 Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom |
| 07/31/2002 | EP1049490B1 Method for inhibiting cd95-independent apoptosis in aids |
| 07/31/2002 | EP0958290B1 1,4-dihydropyridin derivatives and their use in therapy |
| 07/31/2002 | EP0833837B1 Process for preparing derivatives of azabicyclo naphthyridine carboxylic acid comprising a dipeptide |
| 07/31/2002 | EP0799059B1 Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
| 07/31/2002 | EP0764152B1 Substituted indolylmethylene-oxindole analogues as tyrosine kinase inhibitors |
| 07/31/2002 | EP0731699B1 Method of reducing body fat in animals by the administration of conjugated linoleic acid |
| 07/31/2002 | EP0527801B1 Thiophene sulfonamides useful as carbonic anhydrase inhibitors |
| 07/31/2002 | CN1361793A Expression and export of interferon-alpha proteins as Fc fusion proteins |
| 07/31/2002 | CN1361792A Cyclic peptide derivatives as inhibitors of integrin alpha/beta |
| 07/31/2002 | CN1361783A Thiazoloderivatives and pharmaceutical compositions containing them |
| 07/31/2002 | CN1361781A Oxazinocarbazoles for the treatment of CNS diseases |
| 07/31/2002 | CN1361780A Purine derivatives, preparation method and pharmaceutical compositions containing same |
| 07/31/2002 | CN1361779A New compounds |
| 07/31/2002 | CN1361776A Novel fluorinated imidazoline Benzodioxane, preparation and therapeutic uses thereof |
| 07/31/2002 | CN1361775A Novel diphenyl-piperidine derivate |
| 07/31/2002 | CN1361773A Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 07/31/2002 | CN1361768A Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| 07/31/2002 | CN1361767A 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 07/31/2002 | CN1361765A Inhibitors of aspartyl protease |
| 07/31/2002 | CN1361763A Aminobenzophenones as inhibitors of IL-1 beta and TNF_alpha |
| 07/31/2002 | CN1361700A Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| 07/31/2002 | CN1361698A Prolyl endopeptidase inhibitor |
| 07/31/2002 | CN1361697A Use of ginkgo extract |
| 07/31/2002 | CN1361693A Use of 1,4-benzothiazepine derivatives as drugs overcoming carcinostatic tolerance |
| 07/31/2002 | CN1361687A Phosphate transport inhibitors |
| 07/31/2002 | CN1361680A Use of at least one extract of aplant of the genus lannea in a cosmetic or dermopharmaceutical composition |
| 07/31/2002 | CN1360948A Prepn of deactivated dual vibrio vaccine for sea fish |
| 07/31/2002 | CN1360944A Health care pellet for tourist |
| 07/31/2002 | CN1360943A Chinese medicine prepn with functions of resisting senility, resisting fatigue and treating women's asexuality |
| 07/31/2002 | CN1360942A Chinese medicine prepn for treating difficult breath and chest cavity energy-stagnation |